A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer

PURPOSE: (1) To determine the safety of the epidermal growth factor receptor (EGFR) antibody cetuximab with concurrent gemcitabine and abdominal radiation in the treatment of patients with locally advanced adenocarcinoma of the pancreas. (2) To evaluate the feasibility of pancreatic cancer cell epit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Arnoletti, J. P., Frolov, A., Eloubeidi, M., Keene, K., Posey, J., Wood, T., Greeno, Edward, Jhala, N., Varadarajulu, S., Russo, S., Christein, J., Oster, R., Buchsbaum, D. J., Vickers, S. M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3434707/
https://ncbi.nlm.nih.gov/pubmed/20589377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1383-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados